• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞计数与高密度脂蛋白胆固醇比值作为经皮冠状动脉介入治疗患者长期不良结局的新型预测指标:一项回顾性队列研究

White Blood Cell Counts to High-Density Lipoprotein Cholesterol Ratio, as a Novel Predictor of Long-Term Adverse Outcomes in Patients After Percutaneous Coronary Intervention: A Retrospective Cohort Study.

作者信息

Wu Ting-Ting, Zheng Ying-Ying, Xiu Wen-Juan, Wang Wan-Rong, Xun Yi-Li, Ma Yan-Yan, Kadir Patigvl, Pan Ying, Ma Yi-Tong, Xie Xiang

机构信息

Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

Front Cardiovasc Med. 2021 Jul 8;8:616896. doi: 10.3389/fcvm.2021.616896. eCollection 2021.

DOI:10.3389/fcvm.2021.616896
PMID:34307487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8295559/
Abstract

White blood cell (WBC) counts and high-density lipoprotein cholesterol (HDL-C) are widely available in clinical practice. However, the predictive value for cardiovascular disease (CVD) is uncertain. In the present study, we firstly assessed the prognostic value of WBC to HDL-C ratio (WHR) in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI). Six thousand and fifty patients with CAD after PCI from a retrospective cohort study (identifier: ChiCTR-INR-16010153) were evaluated initially. Three hundred and seventy-one patients were excluded due to HDL cholesterol data not available, malignancy, dementia, psoriasis or eczema, systemic connective tissue disorders, multiple sclerosis, chronic liver disease, and chronic obstructive pulmonary disorder. Finally, 5,679 patients were included in the study. The primary outcome was long-term mortality. Secondary endpoints were mainly major adverse cardiovascular and cerebrovascular events (MACCEs), defined as a combination of stroke, cardiac death, stent thrombosis, recurrent myocardial infarction, and target vessel revascularization. The mean follow-up time of this study was 35.9 ± 22.5 months. We defined the best cutoff value of MHR according to the receiver operating curve (ROC), and then patients were divided into high and low WHR groups according to the cutoff value. We analyzed the data in both an acute coronary syndrome group (ACS) and a stable CAD subgroup, respectively. Overall, there were 293 cases of long-term mortality during the follow-up period. According to the cutoff value (WHR = 8.25), 1,901 ACS patients were divided into high WHR group ( = 724) and low WHR group ( = 1,177). Compared to low WHR group, the incidence of all-cause mortality (ACM, 5.5 vs. 3.6%, = 0.048) and cardiac death (4.7vs. 2.9%, = 0.042) were significantly higher in the high WHR group. In stable CAD group, we also found the incidence of ACM and cardiac death were significantly higher in the high group compared to that in the low group. We did not find significant difference between the high and the low WHR group in the incidence of MACCEs. The multivariate Cox proportional hazards model showed that increased WHR level was independently correlated with the mortality. In the high WHR group, the risk of ACM increased two times in ACS [adjusted = 2.036 (1.258-3.296), = 0.004] and 1.5 times in stable CAD [adjusted = 1.586 (1.178-2.136), = 0.002]. The present study indicated that an increased WBC count to HDL-C ratio was independently associated with long-term mortality in CAD patients who underwent PCI.

摘要

白细胞(WBC)计数和高密度脂蛋白胆固醇(HDL-C)在临床实践中广泛可得。然而,其对心血管疾病(CVD)的预测价值尚不确定。在本研究中,我们首先评估了白细胞与高密度脂蛋白胆固醇比值(WHR)在接受经皮冠状动脉介入治疗(PCI)的冠心病(CAD)患者中的预后价值。最初对一项回顾性队列研究(标识符:ChiCTR-INR-16010153)中的6050例PCI术后CAD患者进行了评估。371例患者因无法获得HDL胆固醇数据、患有恶性肿瘤、痴呆、银屑病或湿疹、系统性结缔组织疾病、多发性硬化症、慢性肝病和慢性阻塞性肺疾病而被排除。最终,5679例患者纳入研究。主要结局是长期死亡率。次要终点主要是主要不良心血管和脑血管事件(MACCEs),定义为中风、心源性死亡、支架血栓形成、再发心肌梗死和靶血管血运重建的组合。本研究的平均随访时间为35.9±22.5个月。我们根据受试者工作特征曲线(ROC)确定了MHR的最佳截断值,然后根据该截断值将患者分为高WHR组和低WHR组。我们分别在急性冠状动脉综合征组(ACS)和稳定CAD亚组中分析了数据。总体而言,随访期间有293例长期死亡病例。根据截断值(WHR = 8.25),1901例ACS患者被分为高WHR组(= 724)和低WHR组(= 1177)。与低WHR组相比,高WHR组的全因死亡率(ACM,5.5%对3.6%,= 0.048)和心源性死亡发生率(4.7%对2.9%,= 0.042)显著更高。在稳定CAD组中,我们也发现高组的ACM和心源性死亡发生率显著高于低组。我们未发现高WHR组和低WHR组在MACCEs发生率上有显著差异。多变量Cox比例风险模型显示WHR水平升高与死亡率独立相关。在高WHR组中,ACS患者的ACM风险增加两倍[调整后= 2.036(1.258 - 3.296),= 0.004],稳定CAD患者增加1.5倍[调整后= 1.586(1.178 - 2.136),= 0.002]。本研究表明,白细胞计数与HDL-C比值升高与接受PCI的CAD患者的长期死亡率独立相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e2e/8295559/adb17748d736/fcvm-08-616896-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e2e/8295559/7eb9f76c04cc/fcvm-08-616896-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e2e/8295559/adb17748d736/fcvm-08-616896-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e2e/8295559/7eb9f76c04cc/fcvm-08-616896-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e2e/8295559/adb17748d736/fcvm-08-616896-g0002.jpg

相似文献

1
White Blood Cell Counts to High-Density Lipoprotein Cholesterol Ratio, as a Novel Predictor of Long-Term Adverse Outcomes in Patients After Percutaneous Coronary Intervention: A Retrospective Cohort Study.白细胞计数与高密度脂蛋白胆固醇比值作为经皮冠状动脉介入治疗患者长期不良结局的新型预测指标:一项回顾性队列研究
Front Cardiovasc Med. 2021 Jul 8;8:616896. doi: 10.3389/fcvm.2021.616896. eCollection 2021.
2
An elevated monocyte-to-high-density lipoprotein-cholesterol ratio is associated with mortality in patients with coronary artery disease who have undergone PCI.单核细胞/高密度脂蛋白胆固醇比值升高与接受 PCI 的冠心病患者的死亡率相关。
Biosci Rep. 2020 Aug 28;40(8). doi: 10.1042/BSR20201108.
3
Triglyceride to high-density lipoprotein cholesterol ratio as a predictor of long-term mortality in patients with coronary artery disease after undergoing percutaneous coronary intervention: a retrospective cohort study.三酰甘油与高密度脂蛋白胆固醇比值对经皮冠状动脉介入治疗后冠心病患者长期死亡率的预测作用:一项回顾性队列研究。
Lipids Health Dis. 2019 Dec 4;18(1):210. doi: 10.1186/s12944-019-1152-y.
4
Baseline white blood cell count-to-apolipoprotein A1 ratio as a novel predictor of long-term adverse outcomes in patients who underwent percutaneous coronary intervention: a retrospective cohort study.基线白细胞计数与载脂蛋白 A1 比值作为经皮冠状动脉介入治疗患者长期不良结局的新预测指标:一项回顾性队列研究。
Lipids Health Dis. 2020 Mar 16;19(1):43. doi: 10.1186/s12944-020-01206-w.
5
Rate pressure product as a novel predictor of long-term adverse outcomes in patients after percutaneous coronary intervention: a retrospective cohort study.心率血压乘积作为经皮冠状动脉介入治疗后患者长期不良结局的新预测因子:一项回顾性队列研究。
BMJ Open. 2023 Apr 4;13(4):e067951. doi: 10.1136/bmjopen-2022-067951.
6
Fasting blood glucose to HDL-C ratio as a novel predictor of clinical outcomes in non-diabetic patients after PCI.空腹血糖与高密度脂蛋白胆固醇比值作为预测 PCI 后非糖尿病患者临床结局的新指标。
Biosci Rep. 2020 Dec 23;40(12). doi: 10.1042/BSR20202797.
7
Cystatin C to Left Ventricular Ejection Fraction Ratio as a Novel Predictor of Adverse Outcomes in Patients with Coronary Artery Disease: A Prospective Cohort Study.胱抑素C与左心室射血分数比值作为冠心病患者不良结局的新型预测指标:一项前瞻性队列研究
Rev Cardiovasc Med. 2023 Sep 18;24(9):260. doi: 10.31083/j.rcm2409260. eCollection 2023 Sep.
8
The burden of major adverse cardiac events in patients with coronary artery disease.冠状动脉疾病患者主要不良心脏事件的负担
BMC Cardiovasc Disord. 2017 Jan 4;17(1):1. doi: 10.1186/s12872-016-0436-7.
9
Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.评估 LDL-C/HDL-C 比值对经皮冠状动脉介入治疗和药物洗脱支架置入术后急性冠脉综合征患者一年临床结局的预测价值。
Lipids Health Dis. 2019 Feb 2;18(1):40. doi: 10.1186/s12944-019-0979-6.
10
ALT-to-Lymphocyte Ratio as a Predictor of Long-Term Mortality in Patients with Normal Liver Function Presenting Coronary Artery Disease after Undergoing PCI: A Retrospective Cohort Study.肝肾功能正常的冠心病患者行经皮冠状动脉介入治疗后,天冬氨酸转氨酶与血小板比值预测其长期死亡率的回顾性队列研究。
J Interv Cardiol. 2020 Apr 21;2020:4713591. doi: 10.1155/2020/4713591. eCollection 2020.

引用本文的文献

1
hs-CRP/HDL-C can predict the risk of all cause mortality in cardiovascular-kidney-metabolic syndrome stage 1-4 patients.高敏C反应蛋白/高密度脂蛋白胆固醇可预测心血管-肾脏-代谢综合征1-4期患者的全因死亡风险。
Front Endocrinol (Lausanne). 2025 Apr 10;16:1552219. doi: 10.3389/fendo.2025.1552219. eCollection 2025.
2
Predictive values of novel high‑density lipoprotein‑related inflammatory indices in in‑stent restenosis among patients undergoing elective percutaneous coronary intervention.新型高密度脂蛋白相关炎症指标对择期经皮冠状动脉介入治疗患者支架内再狭窄的预测价值
Exp Ther Med. 2023 Dec 13;27(2):62. doi: 10.3892/etm.2023.12350. eCollection 2024 Feb.
3

本文引用的文献

1
Red blood cell distribution width as long-term prognostic markers in patients with coronary artery disease undergoing percutaneous coronary intervention.红细胞分布宽度作为经皮冠状动脉介入治疗的冠心病患者的长期预后标志物。
Lipids Health Dis. 2019 Jun 12;18(1):140. doi: 10.1186/s12944-019-1082-8.
2
HDL and Reverse Cholesterol Transport.高密度脂蛋白和胆固醇逆向转运。
Circ Res. 2019 May 10;124(10):1505-1518. doi: 10.1161/CIRCRESAHA.119.312617.
3
HDL modification: recent developments and their relevance to atherosclerotic cardiovascular disease.
Role of Lipid Profile and Its Relative Ratios (Cholesterol/HDL-C, Triglyceride/HDL-C, LDL-C/HDL-C, WBC/HDL-C, and FBG/HDL-C) on Admission Predicts In-Hospital Mortality COVID-19.
入院时血脂谱及其相对比值(胆固醇/高密度脂蛋白胆固醇、甘油三酯/高密度脂蛋白胆固醇、低密度脂蛋白胆固醇/高密度脂蛋白胆固醇、白细胞/高密度脂蛋白胆固醇和空腹血糖/高密度脂蛋白胆固醇)对预测 COVID-19 患者院内死亡率的作用
J Lipids. 2023 Mar 6;2023:6329873. doi: 10.1155/2023/6329873. eCollection 2023.
4
Valosin Containing Protein as a Specific Biomarker for Predicting the Development of Acute Coronary Syndrome and Its Complication.含缬酪肽蛋白作为预测急性冠状动脉综合征及其并发症发生的特异性生物标志物。
Front Cardiovasc Med. 2022 Mar 18;9:803532. doi: 10.3389/fcvm.2022.803532. eCollection 2022.
高密度脂蛋白修饰:最新进展及其与动脉粥样硬化性心血管疾病的相关性。
Curr Opin Lipidol. 2019 Feb;30(1):24-29. doi: 10.1097/MOL.0000000000000571.
4
Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases.炎症与动脉粥样硬化:自身免疫性疾病患者的心血管评估。
Autoimmun Rev. 2018 Jul;17(7):703-708. doi: 10.1016/j.autrev.2018.01.021. Epub 2018 May 3.
5
Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank.总白细胞计数和白细胞分类计数与英国生物库心血管疾病和死亡率的关联。
Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1415-1423. doi: 10.1161/ATVBAHA.118.310945. Epub 2018 Apr 26.
6
HDLs and the pathogenesis of atherosclerosis.高密度脂蛋白与动脉粥样硬化的发病机制
Curr Opin Cardiol. 2018 May;33(3):311-316. doi: 10.1097/HCO.0000000000000508.
7
Macrophages and lipid metabolism.巨噬细胞与脂代谢。
Cell Immunol. 2018 Aug;330:27-42. doi: 10.1016/j.cellimm.2018.01.020. Epub 2018 Feb 2.
8
High-density Lipoprotein (HDL) Dysfunction and the Future of HDL.高密度脂蛋白(HDL)功能障碍与 HDL 的未来。
Curr Vasc Pharmacol. 2018;16(5):490-498. doi: 10.2174/1570161115666171116164612.
9
Preprocedural Leucocyte Count Predicts Risk in Patients with Coronary Chronic Total Occlusion.术前白细胞计数可预测冠状动脉慢性完全闭塞患者的风险。
Thromb Haemost. 2017 Nov;117(11):2105-2115. doi: 10.1160/TH17-06-0381. Epub 2017 Nov 30.
10
Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment.急性冠状动脉综合征:从发病机制到精准治疗的未来之路
Circulation. 2017 Sep 19;136(12):1155-1166. doi: 10.1161/CIRCULATIONAHA.117.029870.